223 related articles for article (PubMed ID: 23462214)
1. Efficacy of entecavir switch therapy in chronic hepatitis B patients with incomplete virological response to telbivudine.
Lo AO; Wong VW; Wong GL; Chan HY; Cheung CM; Chan HL
Antivir Ther; 2013; 18(5):671-9. PubMed ID: 23462214
[TBL] [Abstract][Full Text] [Related]
2. Entecavir to Telbivudine Switch Therapy in Entecavir-Treated Patients with Undetectable Hepatitis B Viral DNA.
Kim DH; Choi JW; Seo JH; Cho YS; Won SY; Park BK; Jeon HH; Shin SY; Lee CK
Yonsei Med J; 2017 May; 58(3):552-556. PubMed ID: 28332360
[TBL] [Abstract][Full Text] [Related]
3. Undetectable HBV DNA at month 12 of entecavir treatment predicts maintained viral suppression and HBeAg-seroconversion in chronic hepatitis B patients at 3 years.
Wong GL; Wong VW; Chan HY; Tse PC; Wong J; Chim AM; Yiu KK; Chu SH; Chan HL
Aliment Pharmacol Ther; 2012 Jun; 35(11):1326-35. PubMed ID: 22506552
[TBL] [Abstract][Full Text] [Related]
4. Management options for lamivudine-resistant chronic hepatitis B patients with suboptimal virological suppression by adefovir.
Ong A; Wong VW; Wong GL; Chan HY; Tse CH; Chan HL
Aliment Pharmacol Ther; 2011 Oct; 34(8):972-81. PubMed ID: 21883327
[TBL] [Abstract][Full Text] [Related]
5. Snapshot on drug-resistance rate and profiles in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice.
Salpini R; Alteri C; Cento V; Pollicita M; Micheli V; Gubertini G; De Sanctis GM; Visca M; Romano S; Sarrecchia C; Andreoni M; Angelico M; Parruti G; Svicher V; Perno CF
J Med Virol; 2013 Jun; 85(6):996-1004. PubMed ID: 23588725
[TBL] [Abstract][Full Text] [Related]
6. A comparison of efficacy and safety of 2-year telbivudine and entecavir treatment in patients with chronic hepatitis B: a match-control study.
Tsai MC; Chen CH; Hung CH; Lee CM; Chiu KW; Wang JH; Lu SN; Tseng PL; Chang KC; Yen YH; Hu TH
Clin Microbiol Infect; 2014 Feb; 20(2):O90-O100. PubMed ID: 23659493
[TBL] [Abstract][Full Text] [Related]
7. Real-world application of the roadmap model in chronic hepatitis B patients with telbivudine therapy.
Yu HC; Lin KH; Hsu PI; Tsay FW; Wang HM; Tsai TJ; Lai KH
Clin Ther; 2013 Sep; 35(9):1386-99. PubMed ID: 24054706
[TBL] [Abstract][Full Text] [Related]
8. A 96-week randomized trial of switching to entecavir in chronic hepatitis B patients with a partial virological response to lamivudine.
Heo J; Park JY; Lee HJ; Tak WY; Um SH; Kim DY; Yoon KT; Park SY; Seo YS; Han KH; Cho M; Ahn SH
Antivir Ther; 2012; 17(8):1563-70. PubMed ID: 22872647
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of telbivudine compared with entecavir in hepatitis B virus-related cirrhosis: 2 year follow-up data.
Kim HR; Yim HJ; Kang S; Suh SJ; Kim SY; Hyun JJ; Koo JS; Kim JH; Seo YS; Yeon JE; Lee SW; Byun KS; Um SH
Liver Int; 2015 Mar; 35(3):860-9. PubMed ID: 24905912
[TBL] [Abstract][Full Text] [Related]
10. A comparison of telbivudine and entecavir for chronic hepatitis B in real-world clinical practice.
Tsai MC; Lee CM; Chiu KW; Hung CH; Tung WC; Chen CH; Tseng PL; Chang KC; Wang JH; Lu SN; Yen YH; Hu TH
J Antimicrob Chemother; 2012 Mar; 67(3):696-9. PubMed ID: 22174039
[TBL] [Abstract][Full Text] [Related]
11. Telbivudine versus entecavir in patients with undetectable hepatitis B virus DNA: a randomized trial.
An J; Lim YS; Kim GA; Han SB; Jeong W; Lee D; Shim JH; Lee HC; Lee YS
BMC Gastroenterol; 2017 Jan; 17(1):15. PubMed ID: 28103819
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of telbivudine plus adefovir dipivoxil combination therapy and entecavir monotherapy for HBeAg-positive chronic hepatitis B patients with resistance to adefovir dipivoxil.
Lu JJ; Liu K; Ma YJ; Wang J; Chen EQ; Tang H
J Viral Hepat; 2013 Apr; 20 Suppl 1():40-5. PubMed ID: 23458523
[TBL] [Abstract][Full Text] [Related]
13. A 24-week, parallel-group, open-label, randomized clinical trial comparing the early antiviral efficacy of telbivudine and entecavir in the treatment of hepatitis B e antigen-positive chronic hepatitis B virus infection in adult Chinese patients.
Zheng MH; Shi KQ; Dai ZJ; Ye C; Chen YP
Clin Ther; 2010 Apr; 32(4):649-58. PubMed ID: 20435234
[TBL] [Abstract][Full Text] [Related]
14. Virological response and antiviral resistance mutations in chronic hepatitis B subjects experiencing entecavir therapy: an Indian subcontinent perspective.
Ismail AM; Sharma OP; Kumar MS; Eapen CE; Kannangai R; Abraham P
Antiviral Res; 2013 May; 98(2):209-16. PubMed ID: 23485939
[TBL] [Abstract][Full Text] [Related]
15. [Clinical characteristics and effect of secondary individualized therapy in chronic hepatitis B patients infected with the rtA181 mutation hepatitis B virus].
Ji FZ; Wang L; Yang BH; Zhao JJ; Liu F; Xue Y; Li T
Zhonghua Gan Zang Bing Za Zhi; 2012 Apr; 20(4):280-4. PubMed ID: 22964149
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of entecavir or telbivudine therapy in patients with chronic hepatitis B virus infection pre-treated with interferon compared with de novo therapy with entecavir and telbivudine.
Cai S; Cao J; Yu T; Xia M; Peng J
Medicine (Baltimore); 2017 Jun; 96(22):e7021. PubMed ID: 28562554
[TBL] [Abstract][Full Text] [Related]
17. The 104-week efficacy and safety of telbivudine-based optimization strategy in chronic hepatitis B patients: a randomized, controlled study.
Sun J; Xie Q; Tan D; Ning Q; Niu J; Bai X; Fan R; Chen S; Cheng J; Yu Y; Wang H; Xu M; Shi G; Wan M; Chen X; Tang H; Sheng J; Dou X; Shi J; Ren H; Wang M; Zhang H; Gao Z; Chen C; Ma H; Jia J; Hou J
Hepatology; 2014 Apr; 59(4):1283-92. PubMed ID: 24382690
[TBL] [Abstract][Full Text] [Related]
18. Baseline Hepatitis B Virus DNA Level is a Promising Factor for Predicting the 3 (rd) Month Virological Response to Entecavir Therapy: A Study of Strict Defined Hepatitis B virus Induced Cirrhosis.
Xu Y; Wu XN; Shi YW; Wei W; Yang AT; Sun YM; Zhao WS; You H
Chin Med J (Engl); 2015 Jul; 128(14):1867-72. PubMed ID: 26168824
[TBL] [Abstract][Full Text] [Related]
19. Serum HBV DNA level at week 12 is superior to viral response at week 24 in predicting long-term treatment outcome of telbivudine for chronic hepatitis B patients.
Lü W; Yang HH; Fan YM; Li T; Zhang LF; Mui C; Fan HW; Zhou BT; Liu ZY; Ng H; Liu XQ
Chin Med J (Engl); 2013 Jun; 126(12):2333-6. PubMed ID: 23786949
[TBL] [Abstract][Full Text] [Related]
20. Long-term continuous entecavir therapy in nucleos(t)ide-naïve chronic hepatitis B patients.
Ono A; Suzuki F; Kawamura Y; Sezaki H; Hosaka T; Akuta N; Kobayashi M; Suzuki Y; Saitou S; Arase Y; Ikeda K; Kobayashi M; Watahiki S; Mineta R; Kumada H
J Hepatol; 2012 Sep; 57(3):508-14. PubMed ID: 22659518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
